Second Line T-DM1 Worsens Outcomes for HER2+ Breast Cancer in Real-World Study

Via Peters

Trastuzumab emtansine as a second-line treatment led to shorter median treatment duration and time to treatment failure in patients with HER2-positive metastatic breast cancer who progressed on pertuzumab and trastuzumab–based regimens. Trastuzumab emtansine (T-DM1; Kadcyla) as a second-line treatment led to shorter median treatment duration and time to treatment failure in […]